
The episode discusses peptide testing, HGH safety for women, and strategies for managing weight loss post-menopause.
Medical Disclaimer: We are not doctors. The content in this video is for educational and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Any compounds discussed may be intended for research purposes only. Use at your own risk. Welcome back, warriors! In this week's Peptide Q&A, JD Denham and William T. Haas break down why peptide companies skip advanced testing, how to stack IGF-1 LR3 without overdoing growth pathways, HGH safety for women post-menopause, fixing dangerously low testosterone at 28, and when to pull back Retatrutide and start TRT. Chapters: 00:00 – Intro & Podcast Catch-Up 11:13 – Peptide Testing & Quality Concerns 20:16 – IGF-1, HGH & Stack Overlap 29:20 – Women’s Hormones & Hysterectomy 32:15 – Menopause, Weight Gain & Peptides 44:16 – Peptide Storage & Shelf Life 49:44 – NAD+ Crystallization Explained 51:37 – Growth Hormones for Women (Age 44) 59:44 – Low Testosterone & Mental Health (Age 28) 1:05:48 – Building Muscle Without Steroids (Athlete Q&A) We cover: • Why Peptide Companies Don't Test for Endotoxins & Heavy Metals: The real cost breakdown, why cheap peptides come…
Hosts: JD Denham, William T. Haas
Explore listener stats, chart rankings, contacts and more on the Peptide of The Week podcast page.